A significant number of late-stage readouts for RNAi and antisense therapies are anticipated in 2026 across diverse indications like cardiovascular, neuromuscular, and renal diseases. This signals the growing maturity of these modalities beyond niche applications, with ten Phase 3 trials expected to report data.
China is actively working to become a more attractive market for drug development, exemplified by its new orphan drug exclusivity law. This policy aims to incentivize investment in rare diseases, a previously underdeveloped area, by providing clear market protections.
The UK is emerging as a preferred location for early-stage clinical trials, especially for complex genetic medicines. Its regulator, the MHRA, is becoming more accommodating and efficient, contrasting with what some companies perceive as burdensome FDA requirements in the US.
The discussion points to a deliberate strengthening of UK-China relations, with AstraZeneca's major investments and partnerships in China being publicly supported by the UK government. This is framed as a strategic hedge against geopolitical uncertainty with the US.
The success in IgA nephropathy, where five drugs were approved in five years, demonstrates how a well-defined regulatory pathway using surrogate endpoints can dramatically accelerate development. This success is now being leveraged to advance therapies for other renal diseases.
Keep pulling the thread on Pella Carson.